Enterprise Standard Medetomidine Raw Powder for Central Nervous System Drugs 86347-14-0

Quick Details:

Name:Medetomidine base (86347-14-0)

Synonyms: Medetomidine;4-[1-(2,3-Dimethylphenyl)ethyl]-1H-imidazole; alpha,2,3-trimethylbenzyl)imidazol;1H-Imidazole, 4-(1-(2,3-dimethylphenyl)ethyl)-;86347-15-1 (Hydrochloride);Medetomidina;Medetomidina

CAS NO.: 86347-14-0

Apperance :white powder

MF: C13H16N2

MW:200.2795

Density: 1.053

Mol File: 86347-14-0.mol

Quality Standards: CP/USP/BP/EP 

Package:1kg/foil bag or as your inquiry 

Reference FOB Price:$1/g

MOQ:1kg

Specification:ISO9001,USP,BP,GMP

Trade Mark:CQSP

Port:Shenzhen/Shanghai,China

Production Capacity:5000kg/month

Shipping: DHL, EMS, FedEx, UPS

More details pls contact:Whatapp:86 13048470428  

 Skype/E-mail : summer at chembj.com

Introduction:

Medetomidine is a relatively new sedative analgesic.Medetomidine is a potent and highly specific α2-adrenoreceptor agonist that has been used extensively in Europe and is registered in 34 countries world-wide. It is licensed for IM and IV use only in dogs in Canada and the United States, but in other countries, such as the United Kingdom and Finland, it is approved for use in both dogs and cats. Medetomidine is a lipophillic compound that is rapidly and completely absorbed after IM injection. 

The beneficial effects of medetomidine are the same as those of other α22-agonists and include reliable sedation, analgesia, muscle relaxation, and anxiolysis, as well as a decrease in the anesthetic requirements of injectable and inhalant agents (anesthetic sparing). It is not a controlled substance and, therefore, does not require extensive record keeping. 

Medetomidine COA

TEST SPECIFICATIONS RESULTS

Appearance White or off-white crystalline powder White crystalline powder

Solubility Conforms Conforms

-1 Positive Positive

-2 Conforms Conforms

-3 Positive Positive

Specific rotation +51°~+54° +53.8°

pH 3.5-4.5 4.3

Clarity and Color of Solution Conforms Conforms

Related Substance ≤1.0% 0.20%

The max unknown substance ≤0.1% <0.1%

Levmedetomidine HCL ≤1.0% 0.03%

Loss on drying ≤1.0% 0.19%

Residue on Ignition ≤0.1% 0.07%

Heavy Metal ≤10ppm Conforms

Assay ≥98.5%(anhydrous, containing Medetomidine Hydrochloride) 99.60%

Conclusion The results can conforms with the enterprise standard

Medetomidine beneficial effects

The beneficial effects of medetomidine are the same as those of other α22-agonists and include reliable sedation, analgesia, muscle relaxation, and anxiolysis, as well as a decrease in the anesthetic requirements of injectable and inhalant agents (anesthetic sparing). It is not a controlled substance and, therefore, does not require extensive record keeping. These qualities make medetomidine a viable option in small animal anesthesia. Unfortunately, the negative cardiovascular effects of earlier α2-agonists (xylazine), including bradycardia and associated arrhythmias, hypertension or hypotension, and reduced cardiac output, are still observed with medetomidine and cause concern among clinicians with respect to their use as premedication or sedative agents.